Alzheimer’s Drug Development Comparable To Cancer 50 Years Ago, Says Targacept CEO
This article was originally published in The Pink Sheet Daily
Executive Summary
Biomarkers and diagnostic tools must be developed to allow drug manufacturers to target Alzheimer’s disease modification, BioInvestor Forum panelists say.